Which medication is NOT appropriate for treating invasive aspergillosis?

Invasive aspergillosis is a serious fungal infection that primarily affects immunocompromised patients, such as those undergoing chemotherapy or organ transplantation. The treatment of this condition typically involves using antifungal medications that specifically target the Aspergillus species.

Voriconazole is often the first-line therapy for invasive aspergillosis due to its effectiveness against Aspergillus and favorable pharmacokinetics. Isavuconazole is another azole that has been shown to be effective in treating this infection. Caspofungin, an echinocandin, is also used in cases where azole-resistant strains are suspected or when the patient cannot tolerate azoles.

Amphotericin B, while historically used for a variety of serious fungal infections, including invasive aspergillosis, it is known for its broader spectrum of activity but also comes with significant side effects, including nephrotoxicity. While it can be used, it is not typically the first choice for this specific infection, especially when better-tolerated and more effective antifungals are available.

Therefore, while amphotericin B can still be employed in certain scenarios, it is generally considered less appropriate or less preferred compared to the newer agents like voriconazole and isavuconazole